Background
Methods
Study population
Statistical analyses
Results
Baseline characteristics
Characteristics | CTX group (n = 23) | CYA group (n = 24) | P value |
---|---|---|---|
Men, n (%) | 16 (69.6) | 13 (54.2) | 0.28 |
Age (yrs), mean ± SD | 43 ± 12 | 42 ± 15 | 0.72 |
Body mass index (kg/m2), M (P25, P75) | 25 (23, 29) | 25 (23, 27) | 0.87 |
Serum albumin (g/L), mean ± SD | 26.1 ± 5.3 | 28.0 ± 5.8 | 0.25 |
24hUP (g/d), M (P25, P75) | 8.28 (3.63, 10.98) | 4.73 (3.38, 8.60) | 0.14 |
Nephrotic syndrome, n (%) | 14 (60.9) | 16 (66.7) | 0.68 |
Scr (μmol/L), mean ± SD | 78.7 ± 24.7 | 71.3 ± 19.0 | 0.26 |
eGFR (mL/min per 1.73m2), mean ± SD | 103 ± 28 | 115 ± 24 | 0.15 |
Lymphocyte count (×109/L), mean ± SD | 2.51 ± 1.04 | 2.25 ± 0.81 | 0.32 |
Anti-PLA2R antibody titer (RU/ml), M (P25, P75) | 66.4 (31.5, 192.4) | 63.4 (33.6, 174.0) | 0.69 |
Systolic pressure (mmHg), mean ± SD | 127 ± 8 | 127 ± 14 | 0.995 |
Diastolic pressure (mmHg), mean ± SD | 77 ± 11 | 78 ± 10 | 0.75 |
Changes of serum anti-PLA2R antibody titer after treatment
Characteristics | CTX group (n = 23) | CYA group (n = 24) | P value |
---|---|---|---|
Anti-PLA2R titer (RU/mL), M (P25, P75) | |||
One month | 3.6 (1.6, 58.9) | 30.1 (3.8, 130.7) | 0.04 |
Three months | 1.9 (1.5, 30.7) | 3.9 (2.1, 43.1) | 0.06 |
Six months | 1.7 (1.3, 4.3) | 2.9 (1.6, 36.4) | 0.08 |
Seroconversion of Anti-PLA2R antibody, n (%) | |||
One month | 16 (69.6) | 7 (29.2) | 0.01 |
Three months | 17 (73.9) | 14 (58.3) | 0.26 |
Six months | 18 (78.3) | 16 (66.7) | 0.37 |
Clinical response after treatment
Characteristics | CTX group (n = 23) | CYA group (n = 24) | P value |
---|---|---|---|
24hUP(g/d), M (P25, P75) | |||
One month | 3.37 (2.15, 6.21) | 5.22 (3.08, 10.43) | 0.18 |
Three months | 2.51 (1.28, 4.76) | 4.79 (2.80, 7.22) | 0.03 |
Six months | 1.37 (0.28, 2.41) | 2.26 (1.18, 4.79) | 0.05 |
Endpoint | 0.31 (0.12, 3.48) | 0.38 (0.22, 1.82) | 0.70 |
Scr (μmol/L), M(P25, P75) | |||
Six months | 69 (62, 86) | 77 (59, 85) | 0.48 |
Endpoint | 75 (62, 90) | 72 (58, 79) | 0.38 |
eGFR (ml/min per 1.73m2), mean ± SD | |||
Six months | 97.6 ± 26.5 | 98.4 ± 28.6 | 0.93 |
Endpoint | 97.1 ± 19.6 | 102.9 ± 30.7 | 0.44 |
Lymphocyte counts (×109/L) | |||
One month | 2.73 ± 1.40 | 3.18 ± 1.32 | 0.45 |
Three months | 2.44 ± 1.11 | 3.51 ± 1.57 | 0.01 |
Six months | 2.38 ± 1.29 | 3.37 ± 1.52 | 0.02 |
Endpoint | 2.22 ± 1.07 | 2.49 ± 1.03 | 0.39 |
Response at six-month’s follow -up [n (%)] | |||
Complete remission (CR) | 10 (43.5) | 5 (20.8) | 0.24 |
Partial remission (PR) | 9 (39.1) | 12 (50.0) | 0.24 |
Composite remission (CR + PR) | 19 (82.6) | 17 (70.8) | 0.34 |
No remission (NR) | 4 (17.4) | 7 (29.2) | 0.34 |
Median follow-up time (months), M (P25, P75) | 29 (23, 32) | 29 (15, 34) | 0.92 |
Response at follow-up endpoint, n (%) | |||
Complete remission (CR) | 13 (56.5) | 12 (50.0) | 0.10 |
Partial remission (PR) | 4 (17.4) | 9 (37.5) | 0.10 |
Composite remission (CR + PR) | 17 (73.9) | 21 (87.5) | 0.29 |
No remission (NR) | 3 (13.0) | 1 (4.2) | 0.29 |
Relapse | 3 (13.0) | 2 (8.3) | 0.67 |
Prediction value of antibody titer and 24hUP reduction at early stage for composite remission at six-month follow-up
Characteristics | CTX group (n = 23) | CYA group (n = 24) | P value |
---|---|---|---|
Relative reduction of 24hUP (%), M (P25, P75) | |||
One month | 46.8 (7.2, 67.2) | 4.6 (−57.2, 32.5) | < 0.01 |
Three months | 66.9 (30.9, 78.7) | 22.7 (−66.0, 46.6) | 0.01 |
Six months | 81.0 (68.0, 95.0) | 58.5 (10.8, 79.5) | 0.02 |
Relative reduction of anti-PLA2R titer (%), M (P25, P75) | |||
One month | 94.2 (69.1, 97.3) | 54.6 (−34.9, 94.7) | 0.03 |
Three months | 97.0 (84.2, 98.9) | 92.3 (−15.5, 96.4) | 0.07 |
Six months | 97.0 (93.0, 99.0) | 93.5 (79.3, 97.0) | 0.22 |